LifeMD, Inc 8-K, filed Jun 21, 2021
LifeMD, Inc. (LFMD)
About this 8-K
LifeMD, Inc filed this 8-K on June 21, 2021, reporting on events of June 15, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENT REPORT
Pursuantto Section 13 or 15(d) of the Securities and Exchange Act of 1934
Dateof Report (Date of earliest event reported): June 15, 2021
LIFEMD,INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 001-39785 | 76-0238453 |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission<br><br> <br>File Number) | (IRS Employer<br><br> <br>Identification No.) |
800Third Avenue, Suite 2800
NewYork, NY 10022
(Addressof principal executive offices, including zip code)
(866)351-5907
(Registrant’stelephone number, including area code)
Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| [ ] | Written<br> communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value<br><br> <br>$0.01<br> per share | LFMD | The<br> Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.
COO Compensation
Effective June 15, 2021, LifeMD, Inc. (the “Company”) and Brad Roberts, its Chief Operating Officer, restructured Mr. Roberts’s compensation arrangements. The Company and JDM Investments, LLC mutually terminated Mr. Roberts’s Consulting Services Agreement dated November 26, 2020 (the “Consulting Agreement”), and Mr. Roberts waived all consulting fees due for the remainder of the term of the Consulting Agreement. In place of the Consulting Agreement, Mr. Roberts and the Company amended his Amended and Restated Employment Agreement dated December 21, 2020 (the “Amendment”) to increase his base salary to $475,000 per calendar year and to update the terms of his annual bonus, providing for a target amount of $200,000, with any actual bonus to be awarded in the sole discretion of the Board of Directors.
Item 5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete description of the rights and obligations of the parties to the Consulting Agreement or the Amendment, and such descriptions is qualified in its entirety by reference to the full text of these agreements, which will be filed with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIFEMD, INC. | ||
|---|---|---|
| Dated:<br> June 18, 2021 | By: | /s/ Justin Schreiber |
| Justin<br> Schreiber | ||
| Chief<br> Executive Officer |